Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15904963 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL32680153 | 0.79 | RET (0.32) | RETHTR2AHTR7 | |
| SCHEMBL29440841 | 0.78 | HTR2A (0.35) | RETHTR2AHTR7 | |
| SCHEMBL15904097 | 0.78 | HTR2A (0.35) | RETHTR2AHTR7 | |
| SCHEMBL29440839 | 0.78 | HTR2A (0.33) | HTR2AHTR7 | |
| SCHEMBL15903582 | 0.78 | HTR2A (0.33) | HTR2AHTR7 | |
| SCHEMBL22304321 | 0.77 | ACHE (0.30) | — | |
| SCHEMBL17272854 | 0.77 | CYP17A1 (0.38) | — | |
| SCHEMBL18556188 | 0.76 | — | — | |
| SCHEMBL15905386 | 0.74 | CYP17A1 (0.35) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948149-B1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20240189260-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| CN-117045653-A | Diseases and treatments associated with toxic aldehydes | 奥尔德拉医疗公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-111135171-B | Diseases and treatments associated with toxic aldehydes | 奥尔德拉医疗公司 | 2023-09-08 | — | — | CN | disclosed |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220354857-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20220202745-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| CN-114085236-A | Aldehyde conjugates and uses thereof | 奥尔德拉医疗公司 | 2022-02-25 | — | — | CN | disclosed |
| US-10543181-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190231715-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEXA THERAPEUTICS, INC. | 2019-08-01 | — | — | US | disclosed |
| US-20190125729-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | ALDEYRA THERAPEUTICS, INC. | 2019-05-02 | — | — | US | disclosed |
| US-20180250306-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. | 2018-09-06 | — | — | US | disclosed |
| EP-3337470-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | Aldeyra Therapeutics, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2017-08-24 | — | — | US | disclosed |
| US-9687481-B2 | Toxic aldehyde related diseases and treatment | ALDEYRA THERAPEUTICS, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2017035082-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDEYRA THERAPEUTICS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDEYRA THERAPEUTICS, INC. (F/K/A ALDEXA THERAPEUTICS, INC. F/K/A NEURON SYSTEMS, INC.) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239196-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-20190247334-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-20250127733-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-11771664-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-11701331-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-20180250306-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | RET 3516/4885HTR2A 1765/4885HTR7 2435/4885 |
| US-20220202745-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-20150335632-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-20220354857-A1 | ALDEHYDE CONJUGATES AND USES THEREOF | ALDH1A2, AOX1, ALDH2 | RET 3516/4885HTR2A 1765/4885HTR7 2435/4885 |
| US-20190125729-A1 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION | PDE6C, PDE6D, PDE6A | RET 3481/4885HTR2A 2665/4885HTR7 3249/4885 |
| US-20240189260-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-20190231715-A1 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
| US-10543181-B2 | Toxic aldehyde related diseases and treatment | ALDH1A2, ALDH2, ALDH1A1 | RET 3830/4885HTR2A 944/4885HTR7 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.